Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wilcox, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilcox, M. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, ii27-ii35
© 2003 The British Society for Antimicrobial Chemotherapy

Supplement

Efficacy of linezolid versus comparator therapies in Gram-positive infections

Mark H. Wilcox*

Department of Microbiology, University of Leeds and The General Infirmary, Leeds LS2 9JT, UK

Abstract

Treatment of Gram-positive bacterial infections is currently a therapeutic challenge because many of these pathogens are now resistant to standard antimicrobial agents. The emergence of multidrug-resistant, Gram-positive pathogens emphasizes the need for new antimicrobial therapy. Linezolid is an oxazolidinone antibiotic with a novel mechanism of action that works by inhibiting bacterial protein synthesis by blocking formation of the initiation complex. It is active against Gram-positive organisms resistant to other antibiotics, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae and vancomycin-resistant enterococci (VRE). Results are encouraging from several large-scale, randomized, Phase III trials comparing the efficacy and safety of linezolid with standard comparator agents for the treatment of nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, and infections due to MRSA and VRE. Intravenous/oral linezolid is a promising antimicrobial agent and provides the clinician with an additional treatment option, particularly among the limited therapies for resistant Gram-positive bacterial infections.

Footnotes

* Tel: +44-113-392-6818; Fax: +44-113-343-5649; E-mail: markwi{at}pathology.leeds.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
D. P. Webster, S. Griffiths, and I. C. J. W. Bowler
Failure of linezolid therapy for post-neurosurgical meningitis due to Enterococcus faecium
J. Antimicrob. Chemother., March 1, 2009; 63(3): 622 - 623.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
I. Florescu, M. Beuran, R. Dimov, A. Razbadauskas, M. Bochan, G. Fichev, G. Dukart, T. Babinchak, C. A. Cooper, E. J. Ellis-Grosse, et al.
Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study
J. Antimicrob. Chemother., September 1, 2008; 62(suppl_1): i17 - i28.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. M. Livermore, M. Warner, S. Mushtaq, S. North, and N. Woodford
In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci
Antimicrob. Agents Chemother., March 1, 2007; 51(3): 1112 - 1114.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Ng and I. B. Gosbell
Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp.
J. Antimicrob. Chemother., June 1, 2005; 55(6): 1008 - 1012.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.